KURA ONCOLOGY, INC. Operating Leases, Rent Expense, Net
KURA ONCOLOGY, INC. (KURA) reported Operating Leases, Rent Expense, Net of $500.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeasesRentExpenseNet · last filed 2021-11-04
- KURA ONCOLOGY, INC. operating leases, rent expense, net for the quarter ending 2021-09-30 was $500.00K, a 0.00% change year-over-year.
- KURA ONCOLOGY, INC. operating leases, rent expense, net for the quarter ending 2021-06-30 was $500.00K, a 16.67% decline year-over-year.
- KURA ONCOLOGY, INC. operating leases, rent expense, net for the quarter ending 2021-03-31 was $500.00K, a 66.67% increase year-over-year.
- KURA ONCOLOGY, INC. operating leases, rent expense, net for the quarter ending 2020-12-31 was $600.00K, a 200.00% increase year-over-year.
- KURA ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2020 was $2.00M, a 233.33% increase from fiscal 2019.
- KURA ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2019 was $600.00K, a 20.00% increase from fiscal 2018.
- KURA ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2018 was $500.00K, a 25.00% increase from fiscal 2017.
- KURA ONCOLOGY, INC. operating leases, rent expense, net for fiscal 2017 was $400.00K, a 33.33% increase from fiscal 2016.
| Period end | Operating Leases, Rent Expense, Net 3 month | Operating Leases, Rent Expense, Net 4 month | Operating Leases, Rent Expense, Net 6 month | Operating Leases, Rent Expense, Net 9 month | Operating Leases, Rent Expense, Net 12 month | Operating Leases, Rent Expense, Net 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-09-30 | $500.00K 10-Q · filed 2021-11-04 | $1.00M derived: sum of 2 quarters · filed 2021-11-04 | $1.50M 10-Q · filed 2021-11-04 | $2.10M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2021-06-30 | $500.00K 10-Q · filed 2021-08-05 | $1.00M 10-Q · filed 2021-08-05 | $1.60M derived: sum of 3 quarters · filed 2021-08-05 | $2.10M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2021-03-31 | $500.00K 10-Q · filed 2021-05-06 | $1.10M derived: sum of 2 quarters · filed 2021-05-06 | $1.60M derived: sum of 3 quarters · filed 2021-11-04 | $2.20M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.10M derived: sum of 2 quarters · filed 2021-11-04 | $1.70M derived: sum of 3 quarters · filed 2021-11-04 | $2.00M 10-K · filed 2021-02-24 | ||
| 2020-09-30 | $500.00K 10-Q · filed 2021-11-04 | $1.10M derived: sum of 2 quarters · filed 2021-11-04 | $1.40M 10-Q · filed 2021-11-04 | $1.60M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $600.00K 10-Q · filed 2021-08-05 | $900.00K 10-Q · filed 2021-08-05 | $1.10M derived: sum of 3 quarters · filed 2021-08-05 | $1.20M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $300.00K 10-Q · filed 2021-05-06 | $500.00K derived: sum of 2 quarters · filed 2021-05-06 | $600.00K derived: sum of 3 quarters · filed 2021-05-06 | $700.00K derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $300.00K derived: sum of 2 quarters · filed 2021-02-24 | $400.00K derived: sum of 3 quarters · filed 2021-02-24 | $600.00K 10-K · filed 2021-02-24 | ||
| 2019-09-30 | $100.00K 10-Q · filed 2020-11-05 | $200.00K derived: sum of 2 quarters · filed 2020-11-05 | $400.00K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $100.00K 10-Q · filed 2020-08-06 | $300.00K 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | $100.00K 10-Q · filed 2020-05-04 | |||||
| 2018-12-31 | $500.00K 10-K · filed 2021-02-24 | |||||
| 2017-12-31 | $400.00K 10-K · filed 2020-02-25 | |||||
| 2016-12-31 | $300.00K 10-K · filed 2018-03-12 | $342.00K 10-K · filed 2017-03-14 | ||||
| 2015-12-31 | $267.00K 10-K · filed 2017-03-14 | |||||
| 2014-12-31 | $27.00K 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |